Status:
COMPLETED
Role of Axumin PET Scan in Germ Cell Tumor
Lead Sponsor:
University of Texas Southwestern Medical Center
Conditions:
Testis Cancer
Germ Cell Tumor
Eligibility:
MALE
18+ years
Brief Summary
Investigators will use Axumin PET/CT to help with the imaging modalities to determine the presence of occult retroperitoneal disease.
Detailed Description
Investigators aim to perform a prospective study of anti-18F-FACBC PET/CT in patients with NSGCT prior to RPLND, either in the primary setting or in the post-chemotherapy setting. We will correlate hi...
Eligibility Criteria
Inclusion
- Patients with histologically confirmed NSGCT after orchiectomy who are scheduled to undergo primary RPLND or post-chemotherapy RPLND
- Patients must be over 18 years old and capable and willing to provide informed consent.
- Medically stable as judged by patient's physician.
- Life expectancy must be estimated at \> 6 months.
- Patients must have an ECOG performance status of 0-3 (restricted to ECOG PS 0-2 if age \>70 years).
- Patient must be able to lie still for a 20 to 30 minute PET/CT scan. Patients will be asked if they have problems or issues with lying flat
Exclusion
- Patients with known allergic or hypersensitivity reactions to previously administered radiopharmaceuticals of similar chemical or biologic composition to anti-18F-FACBC are NOT eligible.
- Patients with liver failure are NOT eligible.
- Patients currently undergoing chemotherapy or chemotherapy within two weeks of anti-18F-FACBC PET/CT scan are NOT eligible
Key Trial Info
Start Date :
March 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2023
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT03426865
Start Date
March 1 2018
End Date
June 1 2023
Last Update
August 11 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UT Southwestern Medical Center
Dallas, Texas, United States, 75390